A phase II trial of concurrent chemoradiotherapy with 5-FU plus cisplatin for resectable squamous cell carcinoma of cervical esophagus

A phase II trial of concurrent chemoradiotherapy with 5-FU plus cisplatin for resectable squamous cell carcinoma of cervical esophagus - Ce CRT P-II

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001439

Enrollment

Registered

2009-01-05

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical esophageal cancer

Interventions

5-FU(700mg/m2 d1-4)+ CDDP(70mg/m2 d1) q4w+RT(60Gy) 5-FU(800mg/m2 d1-5)+ CDDP(80mg/m2 d1) q4w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.squamous cell carcinoma of cervical esophagus 2.performance status:0-1 3.have good organ functions 4.out of adaption of endoscopic resection 5.no prior treatment 6.written informed consent to treatment was obtain

Exclusion criteria

Exclusion criteria: 1.have lymph node metastases at neck level II area 2.have active concomitant malignancy 3.A Hbs antigen is positive 4.pregnant or may be pregnant

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Treatment compliance CR rate Progression free survival 3-year larynx preservation survival toxicity	—

Countries

Japan

Contacts

Public ContactSadamoto Zenda

National Cancer Center Hospital East Radiation Oncology Division

szenda@east.ncc.go.jp03-3411-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026